OBJECTIVES: Patients with chronic kidney disease have impaired muscle metabolism, resulting in muscle atrophy. Oxidative stress has previously been identified as a significant contributor to muscle atrophy in other populations, but the contribution in chronic kidney disease is unknown. The aim of this study was to investigate the association between oxidative stress, grip strength, and lean mass in patients with chronic kidney disease. METHODS: This is a cross-sectional study of 152 participants with stage 3 or 4 chronic kidney disease. Outcome measures include grip strength, lean mass, plasma total F2-isoprostanes, inflammation, peak oxygen uptake, and standard clinical measures. RESULTS: Thirty four (22.4%) chronic kidney disease patients had elevated oxidative stress levels (plasma F2-isoprostanes >250 pg/ml), with 82% of patients below age-predicted grip strength normative values. There was a significant negative association between plasma F2-isoprostanes and grip strength (r = -0.251) and lean mass (r = -0.243). There were no associations with inflammation markers. Multiple linear regression identified plasma F2-isoprostanes as a significant predictor of grip strength independent of other predictors: sex, diabetes status, body mass index, body fat percent, and phosphate (adjusted r(2) = 69.5, P < 0.001). DISCUSSION: Plasma F2-isoprostanes were independently associated with reduced strength in chronic kidney disease patients.
OBJECTIVES:Patients with chronic kidney disease have impaired muscle metabolism, resulting in muscle atrophy. Oxidative stress has previously been identified as a significant contributor to muscle atrophy in other populations, but the contribution in chronic kidney disease is unknown. The aim of this study was to investigate the association between oxidative stress, grip strength, and lean mass in patients with chronic kidney disease. METHODS: This is a cross-sectional study of 152 participants with stage 3 or 4 chronic kidney disease. Outcome measures include grip strength, lean mass, plasma total F2-isoprostanes, inflammation, peak oxygen uptake, and standard clinical measures. RESULTS: Thirty four (22.4%) chronic kidney diseasepatients had elevated oxidative stress levels (plasma F2-isoprostanes >250 pg/ml), with 82% of patients below age-predicted grip strength normative values. There was a significant negative association between plasma F2-isoprostanes and grip strength (r = -0.251) and lean mass (r = -0.243). There were no associations with inflammation markers. Multiple linear regression identified plasma F2-isoprostanes as a significant predictor of grip strength independent of other predictors: sex, diabetes status, body mass index, body fat percent, and phosphate (adjusted r(2) = 69.5, P < 0.001). DISCUSSION: Plasma F2-isoprostanes were independently associated with reduced strength in chronic kidney diseasepatients.
Authors: B Payson Oberg; Elizabeth McMenamin; F Lee Lucas; Ellen McMonagle; Jason Morrow; T Alp Ikizler; Jonathan Himmelfarb Journal: Kidney Int Date: 2004-03 Impact factor: 10.612
Authors: Julio C Sartori-Valinotti; Radu Iliescu; Lourdes A Fortepiani; Licy L Yanes; Jane F Reckelhoff Journal: Clin Exp Pharmacol Physiol Date: 2007-09 Impact factor: 2.557
Authors: Shannon B Fadaee; Kassia S Beetham; Erin J Howden; Tony Stanton; Nicole M Isbel; Jeff S Coombes Journal: Redox Rep Date: 2016-04-19 Impact factor: 4.412
Authors: Helena Wallin; Anna M Asp; Carin Wallquist; Eva Jansson; Kenneth Caidahl; Britta Hylander Rössner; Stefan H Jacobson; Anette Rickenlund; Maria J Eriksson Journal: PLoS One Date: 2018-12-19 Impact factor: 3.240
Authors: Mateusz Maciejczyk; Julita Szulimowska; Katarzyna Taranta-Janusz; Anna Wasilewska; Anna Zalewska Journal: J Clin Med Date: 2020-04-29 Impact factor: 4.241
Authors: Mateusz Maciejczyk; Julita Szulimowska; Anna Skutnik; Katarzyna Taranta-Janusz; Anna Wasilewska; Natalia Wiśniewska; Anna Zalewska Journal: J Clin Med Date: 2018-08-10 Impact factor: 4.241